2-MPMDQ

Discontinued Product

0661 has been discontinued.

View all Adrenergic &alpha;<sub>1</sub> Receptors products.
说明: Potent, selective α1 antagonist. Also σ2 ligand
化学名: 2-[[4-(2-Methoxyphenyl)piperazin-1-yl]methyl-6-methyl-2,3-dihydroimidazo[1,2c]quinazolin-5(6H)-one
说明书
引用文献
评论
文献 (1)

生物活性 for 2-MPMDQ

2-MPMDQ is a potent and selective α1-adrenoceptor antagonist; hypotensive.

技术数据 for 2-MPMDQ

分子量 405.5
公式 C23H27N5O2
储存 Store at RT
CAS Number 149847-77-8
PubChem ID 4534085
InChI Key OULFYKAESNCMFJ-UHFFFAOYSA-N
Smiles COC1=C(C=CC=C1)N1CCN(CC2CN3C(=N2)C2=CC=CC=C2N(C)C3=O)CC1

上方提供的技术数据仅供参考。批次相关数据请参见分析证书。

Tocris products are intended for laboratory research use only, unless stated otherwise.

产品说明书 for 2-MPMDQ

分析证书目前不在网上提供。
请联系客户服务

参考文献 for 2-MPMDQ

参考文献是支持产品生物活性的出版物。

Chern et al (1993) Studies on quinazolines. 2,3-Dihydroimidazo[1,2c]quinazoline derivatives. A novel class of potent and selective α1-adrenoceptor antagonists and antihypertensive agents. J.Med.Chem. 36 2196 PMID: 8101878

按标靶查看相关产品

按产品操作查看相关产品

查看全部 Adrenergic α1 Receptor Antagonists

关键词: 2-MPMDQ, 2-MPMDQ supplier, Potent, selective, α1-adrenoceptor, alpha1-adrenoceptor, a1-adrenoceptor, α1-adrenergic, alpha1-adrenergic, a1-adrenergic, antagonists, σ2, sigma2, ligand, Receptors, hypotensive, anti-hypertensive, Adrenergic, Alpha-1, 0661, Tocris Bioscience

篇 2-MPMDQ 的引用文献

引用文献是使用了 Tocris 产品的出版物。

目前没有 2-MPMDQ 的引用文献。

2-MPMDQ 的评论

目前没有该产品的评论。 Be the first to review 2-MPMDQ and earn rewards!

Have you used 2-MPMDQ?

Submit a review and receive an Amazon gift card.

$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image

$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image

Submit a Review

该领域的文献

Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!

*请注意,Tocris 仅会向正规科研企业/机构地址发送文献。


Depression Poster

Depression Poster

Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.